

**Table 1** Description of the studies included – Inclusion and exclusion criteria and sample description

Year First Author Country	Type of UI	Inclusion Criteria	Exclusion Criteria	No of Patients included	Age (Years) BMI Kg/m <sup>2</sup> Parity (n)
2018 Fistic I Croatia	SUI	<ul style="list-style-type: none"> <li>- SUI;</li> <li>- History of vaginal delivery;</li> <li>- Normal cell cytology;</li> <li>- Negative urine culture;</li> <li>- No vulvar or vaginal injuries;</li> <li>- Failure of pelvic floor muscle training.</li> </ul>	<ul style="list-style-type: none"> <li>- Photosensitive disorder or use of photosensitizing drugs;</li> <li>- POP-Q stage <math>\geq</math> II;</li> <li>- UUI;</li> <li>- Severe neurological conditions associated with incontinence;</li> <li>- Neurogenic bladder;</li> <li>- Insulin-dependent diabetes mellitus;</li> <li>- Actual urinary tract infection;</li> <li>- Haematuria;</li> <li>- Age &lt;18 and &gt;70 years;</li> <li>- Pregnancy;</li> <li>- Vaginal delivery within the last 24 weeks;</li> <li>- BMI <math>\geq</math> 35 kg/m<sup>2</sup>;</li> <li>- Injury or/and active infection in the treatment area;</li> <li>- Undiagnosed vaginal bleeding.</li> </ul>	Total: 88 With UI: 88 Lost to follow-up:4	Age 48 (41-54) BMI 23 (21-26) Parity 2 (2-2) Median (IQR)
2017 Behnia-Willison Australia	UUI	<ul style="list-style-type: none"> <li>- Postmenopausal Women not responding or not able to do conventional treatment;</li> <li>- With dyspareunia or vaginal dryness.</li> </ul>	<ul style="list-style-type: none"> <li>- Unexplained bleeding;</li> <li>- Abnormal pap-smear;</li> <li>- Active genital infections;</li> <li>- Active urogenital cancer.</li> </ul>	Total: 102 With UI: NA Lost to follow-up: NA	Age 61 $\pm$ 7 BMI NA Parity NA

					Mean±SD
2017 Gaspar A.Argentina	SUI (type III)	- Type III SUI; - Valsalva leak point pressure (VLPP) of 20–60 cm H <sub>2</sub> O.	- Patients taking alpha-blockers medication; - Previous pelvic radiotherapy or pelvic surgery;	Total: 22	Age
				With UI: 22	57.9 (33-66)
				Lost to follow-up:0	BMI
					27.3 (23-30)
					Parity
					NA
					Mean (Range)
2017 González- Isaza P. Colombia	SUI	- Mild SUI; - Postmenopausal women.	- Anterior Compartment POP-Q stage > II; - Previous surgery; - Recurrent lower urinary tract infection; - BMI >35 kg/m <sup>2</sup> .	Total: 161	Age
				With UI: 161	53±5.1
				Lost to follow-up:0	BMI
					<35
					Parity
					2.5±1
					Mean±SD
2017 Lapii GA Russia	SUI	- Vaginal wall prolapse.	- NA	Total: 18	Age
				With UI: 18	49±12,5
				Lost to follow-up: NA	BMI
					NA
					Parity
					NA
					Mean±SD
2017 Lapii GA Russia	SUI	- Vaginal wall prolapse (POP-Q stage <3).	- NA	Total: 98	Age
				With UI: 98	49±12,5
				With biopsy: 18	BMI

				Lost to follow-up: NA	NA
					Parity
					NA
					Mean±SD
2017 Lin YH Taiwan	SUI (with / without OAB)	- SUI; - OAB symptoms.	- Urinary tract infection; - POP-Q stage > II; - Pregnancy;  - Haematuria; - Childbirth within one year; - Abnormal vaginal bleeding; - Damage of vaginal fascia; - History of spinal cord injury; - Post radical hysterectomy; - Stroke; - Autoimmune disease; - 1-h pad test > 50g.	Total: 30 With UI: 30 Lost to follow-up:0	Age 52.6±8.8 BMI 24.5±3.3 Parity 2.5±0.9 Mean±SD
2017 Pagano I Italy	SUI	- Vaginal atrophy with/or SUI (type 1 or 2); - Negative Pap smear during last 12 months.	- Active urogenital cancer  - Active urogenital infection  - Urge or mixed incontinence  - POP-Q stage > II; - Allergy to LASER.	Total: 33  With UI: 17  Lost to follow-up: NA	Age 52.3±9.9 BMI NA Parity NA Mean±SD
2016 Fistončić N. Croatia	SUI	- History of vaginal delivery; - SUI	- Severe prolapse and damage of the recto-vaginal fascia; - UUI;	Total: 31 With UI: 31	Age 46.8±9.1

		<ul style="list-style-type: none"> <li>- Normal cell cytology;</li> <li>- Negative urine culture;</li> <li>- No local injuries and bleeding.</li> </ul>	<ul style="list-style-type: none"> <li>- Severe neurological conditions associated with incontinence;</li> <li>- Neurogenic bladder;</li> <li>- Insulin-dependent diabetes mellitus;</li> <li>- Urinary tract infection;</li> <li>- Hematuria;</li> <li>- Age <math>\leq 18</math> and <math>&gt;70</math> years;</li> <li>- Pregnancy;</li> <li>- Less than 24 weeks after vaginal delivery;</li> <li>- BMI <math>&gt;30</math>;</li> <li>- Intake of photosensitive drugs;</li> <li>- Local Injury or/and active infection;</li> <li>- Undiagnosed vaginal bleeding.</li> </ul>	Lost to follow-up: 17	BMI 23.3 $\pm$ 2.7 Mean $\pm$ SD Parity 2 (1.7-3) Median (IQR)
2016 Pardo JI. Chile	SUI	- Mild to severe SUI.	<ul style="list-style-type: none"> <li>- Exclusive UI;</li> <li>- Severe prolapse;</li> <li>- Pregnancy;</li> <li>- Previous surgery due to treated condition;</li> <li>- Patients with severe neurological conditions;</li> <li>- Vaginal lesions;</li> <li>- Genitourinary tract infections;</li> <li>- Abnormal vaginal bleeding;</li> <li>- History of photosensitivity disorder or use of photosensitizing drugs;</li> <li>- Hematuria.</li> </ul>	Total: 42 With UI: 42 Lost to follow-up:0	Age 46.5 (30-79) BMI NA Parity 2 (0-5) Median (Range)
2016 Perino A. Italy	UI	<ul style="list-style-type: none"> <li>- Post-Menopausal women;</li> <li>- <math>\geq 1</math> vulvovaginal symptoms</li> <li>- Non-response to previous estrogen or local therapies;</li> <li>- OAB</li> </ul>	<ul style="list-style-type: none"> <li>- Clinically significant bladder outflow obstruction;</li> <li>- Post-void residual (PVR) volume <math>&gt;200</math>ml;</li> <li>- associated SUI;</li> <li>- Diabetic neuropathy;</li> <li>- Use of concomitant urinary incontinence or psychotropic</li> </ul>	Total: 30 With UI: 9 Lost to follow-up:0	Age 56 (8.5) BMI 23.9 (3.49) Parity

			medications; - Symptomatic urinary tract infection; - Active genital infections; - Previous pelvic radiation therapy; - Previous or current malignant disease of the pelvic organs; - POP-Q stage.>II; - Use of any form of HRT within the previous 6 months.		1 (1.25) Median (IQR)
2016 Pitsouni E. Greece	UII	- Menopause;  - <sup>3</sup> 1 symptom of genitourinary syndrome of menopause (GSM) with moderate-severe intensity and clinical signs of GSM.	- Use of any form of hormone therapy (HRT) within the previous 6 months; - Use of lubricants or vaginal moisturizers within the last month;  - Active genital infections;  - POP-Q stage ≥ II.	Total: 53  With UI: 53  Lost to follow-up:0	Age  57.2±5.4  BMI 26.0±4.8 Parity NA Mean±SD
2016 Tien YW. Taiwan	SUI (with / without OAB)	- SUI; - Sexually active.	- Undiagnosed abnormal vaginal bleeding.	Total: 35 With UI: 35 Lost to follow-up:2	Age 43.3±7.2 BMI 24.0±3.2 Parity 1.8±1.2 Mean±SD
2015 Gambacciani M.a Italy	SUI	- Post menopausal women; - Genitourinary syndrome; - FSH > 40U/L, E2<25pg/mL;  - Negative pap smear.	- Vaginal lesions or scars; - Active or recent (30 days) genitourinary tract infections; - Abnormal uterine bleeding;  - Use of lubricants or any other local preparations 30 days before	Total: 45 With UI: 19 Lost to follow-up:2	Age 60.9±8.1 BMI 26.1±3.3

			<ul style="list-style-type: none"> <li>- History of photosensitivity disorder or use of photosensitizing drugs;</li> <li>- POP-Q stage <math>\geq</math>II;</li> <li>- Serious or chronic condition that could interfere with study compliance;</li> <li>- Treatment with medicines to relieve menopausal symptoms 12 months before.</li> </ul>		Parity 12,5 $\pm$ 5,8 Mean $\pm$ SD
2015 Gambacciani M.b Italy	SUI	<ul style="list-style-type: none"> <li>- Post menopausal women;</li> <li>- Genitourinary syndrome;</li> <li>- FSH &gt; 40U/L, E2&lt;25pg/mL;</li> <li>- Negative pap smear.</li> </ul>	<ul style="list-style-type: none"> <li>- Vaginal lesions or scars;</li> <li>- Active or recent (30 days) genitourinary tract infections;</li> <li>- Abnormal uterine bleeding;</li> <li>- Use of lubricants or any other local preparations 30 days before</li> <li>- History of photosensitivity disorder or use of photosensitizing drugs;</li> <li>- POP-Q stage <math>\geq</math>II;</li> <li>- Serious or chronic condition that could interfere with study compliance;</li> <li>- Treatment with medicines to relieve menopausal symptoms 12 months before.</li> </ul>	Total: 69 With UI: 21 Lost to follow-up: 2	Age 62.9 $\pm$ 8.1 BMI 27.5 $\pm$ 2.3 Parity NA Mean $\pm$ SD
2015 Fistončić N. Croatia	SUI	<ul style="list-style-type: none"> <li>- History of vaginal delivery;</li> <li>- SUI;</li> <li>- Normal cell cytology;</li> <li>- Negative urine culture;</li> <li>- Free of local injuries or bleeding.</li> </ul>	<ul style="list-style-type: none"> <li>- Severe prolapse and damage of the recto vaginal fascia;</li> <li>- UUI;</li> <li>- Severe neurological conditions associated with incontinence;</li> <li>- Neurogenic bladder;</li> <li>- Insulin-dependent diabetes mellitus;</li> <li>- Actual urinary tract infection;</li> <li>- Hematuria;</li> <li>- Age <math>\leq</math>18 and &gt;70 years;</li> <li>- Pregnancy;</li> <li>- Less than 24 weeks after vaginal delivery;</li> <li>- BMI &gt; 35kg/m<sup>2</sup>;</li> <li>- Intake of photosensitive drugs;</li> <li>- Injury or/and active infection in the treatment area;</li> </ul>	Total: 73 With UI: 73 Lost to follow-up:28	Age 47 (41-54) BMI 23 (21-25) Parity 2 (2-3) Median (IQR)

2015 Ogrinc UB. Slovenia	SUI and MUI	- Clinically confirmed UI;	- Undiagnosed vaginal bleeding.	Total: 175	Age
		- Normal PAP smear;	- Pregnancy;	With UI: 175	49.7±10
		- Negative urine culture;	- Intake of photosensitive drugs;	Lost to follow-up:0	Mean±SD
		- Integrity of the vaginal mucosa.	- Injuries or vaginal bleeding;		BMI
			- Infection in the treated area;		- Underweight 2%
			- Pure UUI.		- Normal 58%
					- Overweight 29%
					- Obese 12%
					Parity
					NA

NA, Not Applicable; BMI, Body Mass Index; UI, Urinary Incontinence; SUI, Stress UI; MUI, Mixed UI; UU, Urge UI; OAB, Overactive Bladder; SD, Standard Deviation; IQR, Interquartile Range; POP-Q, Pelvic Organ Prolapse Quantification

**Table 2** Description of the studies included – Laser protocol, follow-up, Primary and secondary outcomes

Year First Author Country	LASER Protocol	Follow-up	Patient Reported Outcomes (Questionnaires)	Other Outcomes	Safety / Adverse Effects
2018 Fistonic I Croatia	LASER: Er:YAG	Baseline, F1: 2-6 months.	ICIQ-UI-SF score	Q-tip test (degrees) – Valsalva Manoeuvre	During Sessions:
	Sessions: 1		B: 12.0 (7.5-16.0)	B: 72.5 (48.8-80)	NA
	Interval: -		F1: 6 (0-11) (p<0.001)	F1: 50 (30-70) (p<0.001)	
	Anaesthesia: NA		Median (IQR)		After treatment:
	Concomitant Therapies: NA Sexual abstinence: NA		Predictors of greater ICIQ-score improvement: Age BMI	Residual Volume (mL)  B: 2.9 (0.8-9.4)  F1: 0.5 (0-1.7) (p<0.001)	NA

			Basal Q-tip test	Perineometry – Avarage (mmHg)	
			Basal ICIQ-UI test	B: 5.3 (4.2-7.3)	
				F1: 6.4 (4.8-11.1) (p=0.018)	
			Non predictors of greater ICIQ-score improvement:	Perineometry – Maximum (mmHg)	
			Parity	B: 10.5 (8-14)	
			Birth weight	F1: 11.3 (8.4-17.8) (p=0.001)	
			Menopause	Perineometry – Duration (seconds)	
			Basal Perineometry	B: 8.5 (5-14.3)	
				F1: 12.1 (6.1-18.3) (p=0.001)	
				Median (IQR)	
2017 Behnia-Willison Australia	LASER: CO2 Sessions: 3 Interval: $\geq 6$ weeks Anaesthesia: No Concomitant Therapies: vulvar silicon-based balm post procedure Sexual abstinence: 5 days	Baseline, F1: after last treatment, F2: 12-24 months.	Subjective Evaluation of UUI improvement F1 to F2: 51% (p=0.003) F2 to F3: 53% (p<0.001) Percentage of patients that improved	NA	During Sessions:  NA  After treatment: Postcoital urinary tract infection (2.9%)  Vaginal discharge (1.9%) Transient pelvic pain (2.9%) Herpes Brakout (1%) Postmenopausal bleeding (1.9%)
2017 Gaspar A. Argentina	LASER: Er:YAG Sessions: 2 Interval: 3 weeks Anaesthesia: No	Baseline, F1: 3 months, F2: 6 months.	ICIQ-UI-SF score B: 18 F1: 5 (p<0.001) F2: 8 (p<0.001)	1-h pad weight test B: 23g F1: 10g   18 (82%) (p<0.001) F2: 14g   11 (50%) (p<0.001)	During Sessions: Well tolerated  After laser therapy:



	Concomitant Therapies: vitamin C 2 g/day for 3 months; vitamin A 50,000 UI/day for 3 months; ciprofloxacin 1g 2h before intervention. Local estriol before treatment (when needed) Sexual abstinence: 3 days		Mean (significance is versus Baseline)	Pad weight mean   number of patients that improved (%) (significance is versus Baseline)	pelvic pain (n=1), dysuria (n=2). Both effects disappeared within 24h
2017 González- Isaza P. Colombia	LASER: CO <sub>2</sub> Sessions: 4 Interval: 30-45d Anaesthesia: NA Concomitant Therapies: 36% under HRT Sexual abstinence: NA	Baseline, F1: 12 months, F2: 24 months, F3: 36 months.	ICIQ-UI-SF score B: 14.34±2.65 F1: 7.09±1.1 (p<0.001) F2: 7.49±0.94 (p<0.001) F3: 6.76±0.82 (p<0.001) Mean±SD (significance is versus Baseline)	1-h pad weight test B: 9.89±0.57g F1: 3.52±1.89g (p<0.001) F2: 3.55±1.88g (p<0.001) F3: 3.72±2.05g (p<0.001) Mean ±SD (significance is versus Baseline) (NS if compared F1-F2, F2-F3, F1- F3) Histologic Examination 6 weeks after: Thicker epithelium with a higher population of intermediate and shedding superficial cells. The stroma with features indicating structural recovery.	Well tolerated. No side effects.
2017 Lapii Gaa Russia	LASER: Er:YAG Sessions: 1 Interval: - Anaesthesia: NA Concomitant Therapies: N/A	Baseline, F1: 1,5-2 months.	NA	Index of Ki-67 (Proliferative activity) B: 19.05±2.86% F1: 31.79±2.25 (p<0.05) Mean ±SD	NA

Sexual abstinence: NA					
2017 Lapii Gab Russia	LASER: Er:YAG	Baseline,	NA	Thickness of the Epithelium	NA
	Sessions: 2	F1: 1,5-2 months.		B: 114.19±17.31µm	
	Interval: 1-1.5 months			F1: 187.83±15.35µm (p<0.05)	
	Anaesthesia: NA			Volume density of capillaries	
	Concomitant Therapies: N/A Sexual abstinence: NA			B: 1.8±0.2% F1: 2.9± 0.3% (p<0.01)	
				Number of capillary profiles	
				B: 8.5±0.63	
				F1: 12.1±1.07 (p<0.05)	
				Vessels diameter	
				B: 6.43±0.33µm	
				F1: 7.14±0.35µm (NS)	
				Mean±SD	
2017 Lin YH Taiwan	LASER: Er:YAG	Baseline,	ICIQ-UI-SF score	1-h pad weight test	Major Events: None
	Sessions: 2	F1: 1 month,	B: 10.0±3.7	B: 13.2±17.7g	
	Interval: 4 weeks	F2: 3 months,	F1: 7.1±4.0	F1: 9.7±15.1g	During Sessions:
	Anaesthesia: No	F3: 12 months.	F2: 6.8±4.0 (p=0.002)	F2: 6.1±11.6g (p=0.039)	Mild tolerable pain; burning sensation.
	Concomitant Therapies: N/A Sexual abstinence: 3 days		F3: 5.5±4.2 (p=0.001)	Mean±SD	[VAS pain score 4.2±2.0]
				(significance is versus Baseline)	
				OAB symptom score	After treatment:
				B: 8.2±5.0	Few patients with transient increased vaginal discharge, spotting.

F1: 7.1±2.1  
 F2: 6.1±4.3 (p=0.027)  
 F2: 7.9±6.0 (NS)  
 UDI-6 score  
 B: 8.9±4.3  
 F1: 6.6±3.7  
 F2: 5.4±3.6 (p<.001)  
 F2: 7.3±4.6 (NS)  
 IIQ-7 score  
 B: 6.9±6  
 F1: 6.9±5.9  
 F2: 5.1±5.2 (NS)  
 F2: 6.5±8.3 (NS)  
 Mean±SD (significance is versus  
 Baseline)

2017 Pagano I Italy	LASER: CO2 Sessions: 3  Interval: 1 month Anaesthesia: No Concomitant Therapies: NA Sexual abstinence: NA	Baseline, F1: 3 months (after last session).	ICIQ-UI-SF score	Histological examination	During Sessions:
			B: 9.7±4.0  F1: 7.1±4.2 (p<0.05)  A - Surgical menopause  B: 9.5±4.3 F1: 7.0±3.3 (p<0.05) B – Physiological menopause B: 10.0±4.0 F1: 7.2±5.1 (p<0.05) Mean±SD	Significant increase in the thickness and staining of type III collagen of the epithelium	None   After treatment: None
2016 Fistonic	LASER: Er:YAG	Baseline,	ICIQ-UI-SF score	Residual Urine:	During Sessions:

N. Croatia	Sessions: 1	F1: 1 month,	B: 12.9±5	B: 3.8 (1.1-10.5)	Warmth or teasing sensation (all patients)
	Interval: -	F2: 2 months,	F1: 6.6±6.1 (p<0.001)	F1: 0.6 (0.1-3.3) (p=0.01)	
	Anesthesia: NA	F3: 6 months.	F2: 7.6±6.7 (p<0.01)	F2: 0.4 (0.2-3.7) (p= 0.04)	After treatment:
	Concomitant Therapies: NA		F3: 7.8±5.7 (p<0.05)	F3: 1.0 (0.2-3.3) (p=0.07)	Few patients with transient vaginal discharge and slight vulvar edema
	Sexual abstinence: NA		Mean±SD	Median (IQR)	
				Perineometry	
				No statistically significant differences	
2016 Pardo JI. Chile	LASER: Er:YAG Sessions: 2 Interval: 21-28 d	Baseline, F1: 3-6 months.	ICIQ-UI-SF score B: 11 (6) F1: 3 (10) (p < 0.001)	NA	During Sessions: Well tolerated. Some patients with mild pain
	Anesthesia: Topic Concomitant Therapies: Local estriol before treatment (when needed) Sexual abstinence: 3 days		- Complete Healing: 38.1% - Improvement: 78.6 %  - No change: 16,7% - Worse: 4,8% Median (IQR)		After treatment:  None
2016 Perino A. Italy	LASER: CO2 Sessions: 3 Interval: ≥ 1 month Anesthesia: No Concomitant Therapies: No	Baseline, F1: 30 days (after last session).	OAB-Q-SF score B: 18.5 (4.25) F1: 8 (2.25) (p<0.0001) Median (IQR)	NA	During Sessions: None  After treatment None

	Sexual abstinence: NA				
2016 Pitsouni E. Greece	LASER: CO2	Baseline,	ICIQ-UI-SF score	NA	During Sessions:
	Sessions: 2	F1: 12 weeks.	B: 8.1±5.6		None
	Interval: 1 month		A: 3.4±4.3 (p<0.001)		
	Anesthesia: NA				After treatment:
	Concomitant Therapies: NA		ICIQ-FLUTS score		Temporary (2h) mild irritation of the introitus.
	Sexual abstinence: NA		B: 3.6±2.4		
			F1: 1.6±1.5 (p<0.001)		
			UDI-6 score		
			B: 30.2±21.4		
			F1: 11.9±16.6 (p<0.001)		
			Mean±SD		
2016 Tien YW. Taiwan	LASER: Er:YAG	Baseline,	PPBC score:	20 minutes Pad weight:	During Sessions:
	Sessions: 1	F1: 3 months,	B: 2.7±1.0	B: 14.0±18.2g	None
	Interval: -	F2: 6 months.	F1: 2.0±1.2 (p<0.001)	F1: 6.1±13.1g (p<0.001)	
	Anesthesia: Topic		F2: 2.0±1.1 (p<0.001)	F2: 3.1±5.6g (p<0.001)	After treatment
	Concomitant Therapies: NA			Mean±SD	None
	Sexual abstinence: NA		USS score	(significance is versus Baseline)	
			B: 1.3±0.8		
			F1: 0.6±0.8 (p<0.01)	Urodynamic tests	
			F2: 0.8±0.7 (p=0.01)	No statistically significant differences	
			OAB symptom score		
			B: 4.1±2.8		
			F1: 3.1±2.9 (p<0.001)		
			F2: 2.7±2.6 (p<0.001)		
			UDI-6 score		

			B: 4.1±2.9 F1: 2.8±3.0 (p<0.001) F2: 3.1±3.1 (p<0.001) IIQ-7 score B: 3.2±4.2 F1: 2.2±4.2 (p<0.05) F2: 2.7±4.9 (p<0.05) Mean±SD (significance is versus Baseline)		
2015 Gambacciani M.a Italy	LASER: Er:YAG Sessions: 3  Interval: 1 month Anesthesia: No Concomitant Therapies: NA Sexual abstinence: 1 week	Baseline, F1: 4 weeks,  F2: 12 weeks, F3: 24 weeks.	ICIQ-UI-SF score B: 12.0±1.8  F1: 5.5±2.6 (P<0.01) F2: 5.5±2.9 (P<0.01) F3: 5.0±2.6 (P<0.01)  Mean±SD (significance is versus Baseline)	NA	During Sessions:  Discontinuation because of side effects: 3%  After treatment: Burning sensation: 2.2%
2015 Gambacciani M.b Italy	LASER: Er:YAG Sessions: 3 Interval: 1 month  Anesthesia: No  Concomitant Therapies: NA Sexual abstinence: 1 week	Baseline, At each session, F1: 4 weeks  (After last session).	ICIQ-UI-SF score No score available  Significant improvement at all evaluations comparing to baseline (p<0.01)	NA	During Sessions: NA  After treatment NA
2015 Fistonić N. Croatia	LASER: Er:YAG Sessions: 1	Baseline, F1: 1 month,	ICIQ-UI-SF score B: 12.0 (6.0-16.0)	ICIQ-SF score by BMI The decrease was significantly stronger in normal vs. Overweight (p=0.008)	During Sessions: Warmth or pickling sensation

	Interval: - Anaesthesia: No Concomitant Therapies: NA	F2: 2-6 months.	F1: 4.0 (0.0-10.8) (p<0.001) F2: 4.0 (0.0-11.0) (p<0.001) Median (IQR)	ICIQ-SF score by BMI The decrease was significantly and inversely correlated with age (p<0.001)	After treatment: Transient (48h) increased vaginal discharge, Slight vulvar edema De novo UUI: 1.4%
	Sexual abstinence: NA		(significance is versus Baseline)		
2015 Ogrinc UB. Slovenia	LASER: Er:YAG	Baseline,	ICIQ-UI-SF (ISI score)	ICIQ-SF – ISI improvement by grade of UI	During Sessions:
	Sessions: 2-3	F1: 2 months,	F1 to F2: Statistically significant improvement	Mild UI: 2.6±1.0 (p<0.001)	Mild discomfort (mean VAS score: 0.5)
	Time: 0, 1, 6m	F2: 6 months,	F2 to F3: No statistically significant differences	Moderate UI: 3.6±1.4 (p<0.001)	
	Anaesthesia: No Concomitant Therapies: No Sexual abstinence: 1 week	F3: 12 months.		Severe IU: 5.7±1.8 (p<0.001) Very Severe: 8.4±2.6 (p<0.001) (Mean±SD)	After treatment: Transient UUI: 6.3%  De novo UUI: 4%
				ICIQ-SF – ISI improvement by type of UI SUI: 77% MUI: 34% (p<0.001) ICIQ-SF – ISI Improvement by age No statistically significant differences UUI appeared de novo in 4%	

NA, not applicable; B, baseline; F, follow-up; BMI, body mass index; SD, standard deviation; IQR, interquartile range; NS, not significant; CO<sub>2</sub>, microablative fractional CO<sub>2</sub>-laser; Er:YAG, non-ablative photothermal Erbium: YAG-laser; UI, urinary incontinence; UUI, urge UI; ICIQ, international consultation on incontinence questionnaire; ICIQ-UI-SF, ICIQ-urinary incontinence-short form; ICIQ-FLUTS, ICIQ-female low urinary tract symptoms; ISI, incontinence severity index; IIQ-7, incontinence impact questionnaire-7; OAB, overactive bladder; OAB-Q SF, OAB-questionnaire-short form; PPBC, patient perception of bladder condition; UDI-6, urogenital distress inventory-6; USS, urgency severity scale